$NTHI
Neonc Technologies Holdings, Inc. develops novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. Its lead products in development include NEO100, which is in Phase 2a clinical trials for treating glioblastoma; and NEO212, a covalently conjugated molecule combining the chemotherapeutic drug temozolomide with perillyl alcohol that is completed preclinical testing. The company was incorporated in 2023 and is based in Los Angeles, California.
Healthcare
Sector
Biotechnology
Industry
Amir Farrokh Heshmatpour
CEO
8
Employees
$7.31
Current Price
$179.65M
Market Cap
Insider Activity Statistics
Aggregated buying and selling activity by time period
| Period | Type | Insiders | Transactions | Value | Shares | Buy/Sell Ratio |
|---|---|---|---|---|---|---|
| 1 week | Buys | 0 | 0 | - | - | - |
| Sells | 0 | 0 | - | - | ||
| 2 weeks | Buys | 0 | 0 | - | - | - |
| Sells | 0 | 0 | - | - | ||
| 1 month | Buys | 0 | 0 | - | - | - |
| Sells | 0 | 0 | - | - | ||
| 2 months | Buys | 0 | 0 | - | - | - |
| Sells | 0 | 0 | - | - | ||
| 3 months | Buys | 0 | 0 | - | - | - |
| Sells | 0 | 0 | - | - | ||
See activity going back 12 months โ create a free account | ||||||
Insider Transactions
Recent purchases and sales by company insiders
No transactions in the last 3 months. Sign up free to see 12 months of history.
Upcoming Earnings
Scheduled earnings reports
EPS
Estimated-$0.37
ActualN/A
Revenue
EstimatedN/A
ActualN/A
Past Earnings
Historical earnings results
EPS
Estimated-$0.37
ActualN/A
Revenue
EstimatedN/A
ActualN/A
EPS
Estimated-$0.37
ActualN/A
Revenue
EstimatedN/A
ActualN/A
EPS
EstimatedN/A
ActualN/A
Revenue
EstimatedN/A
ActualN/A
EPS
EstimatedN/A
ActualN/A
Revenue
EstimatedN/A
ActualN/A
1 more earnings records available โ create a free account to see 12 months of history
Related Activity
Cross-company insider connections and cluster buy signals